Dyne Therapeutics, Inc. Financing Cash Flow
Dyne Therapeutics, Inc. (DYN) reported Financing Cash Flow of $65.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-29
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $58.11M, a 42.34% decline year-over-year.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.06M, a 95.00% decline year-over-year.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $430.96M, a 11752.72% increase year-over-year.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $217.33M, a 1106.77% increase year-over-year.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $890.31M, a 9.93% increase from fiscal 2024.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $809.89M, a 1390.92% increase from fiscal 2023.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $54.32M, a 45.28% increase from fiscal 2022.
- Dyne Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $37.39M, a 76.31% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $65.17M 10-Q · filed 2026-07-29 | $496.14M derived: sum of 3 quarters · filed 2026-07-29 | $713.47M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $7.06M 10-Q · filed 2026-05-11 | $438.03M derived: sum of 2 quarters · filed 2026-05-11 | $655.36M derived: sum of 3 quarters · filed 2026-05-11 | $756.13M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $430.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $648.29M derived: sum of 2 quarters · filed 2026-03-02 | $749.07M derived: sum of 3 quarters · filed 2026-07-29 | $890.31M 10-K · filed 2026-03-02 |
| 2025-09-30 | $217.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $318.10M derived: sum of 2 quarters · filed 2026-07-29 | $459.34M 10-Q · filed 2025-11-05 | $462.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $100.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $242.01M 10-Q · filed 2026-07-29 | $245.65M derived: sum of 3 quarters · filed 2026-07-29 | $263.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $141.24M 10-Q · filed 2026-05-11 | $144.88M derived: sum of 2 quarters · filed 2026-05-11 | $162.89M derived: sum of 3 quarters · filed 2026-05-11 | $542.75M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $21.64M derived: sum of 2 quarters · filed 2026-03-02 | $401.51M derived: sum of 3 quarters · filed 2026-03-02 | $809.89M 10-K · filed 2026-03-02 |
| 2024-09-30 | $18.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $397.87M derived: sum of 2 quarters · filed 2025-11-05 | $806.26M 10-Q · filed 2025-11-05 | $806.41M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $379.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $788.25M 10-Q · filed 2025-07-28 | $788.40M derived: sum of 3 quarters · filed 2026-03-02 | $788.85M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $408.39M 10-Q · filed 2025-05-08 | $408.54M derived: sum of 2 quarters · filed 2026-03-02 | $408.99M derived: sum of 3 quarters · filed 2026-03-02 | $433.89M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $601.00K derived: sum of 2 quarters · filed 2026-03-02 | $25.51M derived: sum of 3 quarters · filed 2026-03-02 | $54.32M 10-K · filed 2026-03-02 |
| 2023-09-30 | $454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $25.36M derived: sum of 2 quarters · filed 2024-11-12 | $54.17M 10-Q · filed 2024-11-12 | $91.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $24.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $53.72M 10-Q · filed 2024-08-12 | $90.92M derived: sum of 3 quarters · filed 2025-02-27 | $90.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $28.82M 10-Q · filed 2024-05-02 | $66.02M derived: sum of 2 quarters · filed 2025-02-27 | $66.09M derived: sum of 3 quarters · filed 2025-02-27 | $66.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $37.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $37.27M derived: sum of 2 quarters · filed 2025-02-27 | $37.37M derived: sum of 3 quarters · filed 2025-02-27 | $37.39M 10-K · filed 2025-02-27 |
| 2022-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $169.00K derived: sum of 2 quarters · filed 2023-10-30 | $187.00K 10-Q · filed 2023-10-30 | $276.00K derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $117.00K 10-Q · filed 2023-08-03 | $206.00K derived: sum of 3 quarters · filed 2023-08-03 | $663.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $18.00K 10-Q · filed 2023-05-11 | $107.00K derived: sum of 2 quarters · filed 2023-05-11 | $564.00K derived: sum of 3 quarters · filed 2023-05-11 | $589.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $546.00K derived: sum of 2 quarters · filed 2023-03-02 | $571.00K derived: sum of 3 quarters · filed 2023-03-02 | $157.82M 10-K · filed 2023-03-02 |
| 2021-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $482.00K derived: sum of 2 quarters · filed 2022-11-03 | $157.73M 10-Q · filed 2022-11-03 | $146.54M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $157.28M 10-Q · filed 2022-08-04 | $146.08M derived: sum of 3 quarters · filed 2022-08-04 | $526.06M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $157.25M 10-Q · filed 2022-05-02 | $146.06M derived: sum of 2 quarters · filed 2022-05-02 | $526.03M derived: sum of 3 quarters · filed 2022-05-02 | $526.03M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | -$11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $368.78M derived: sum of 2 quarters · filed 2022-03-10 | $368.78M derived: sum of 3 quarters · filed 2022-03-10 | $380.69M 10-K · filed 2022-03-10 |
| 2020-09-30 | $379.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $379.98M derived: sum of 2 quarters · filed 2021-11-04 | $391.88M 10-Q · filed 2021-11-04 | $391.88M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.91M 10-Q · filed 2021-08-05 | $11.91M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $11.91M 10-Q · filed 2021-05-06 | $11.91M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $19.99M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $19.99M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |